Maryland Sen. Angela Alsobrooks (D) and Oregon Sen. Ron Wyden (D) have taken a stand on a national health‑policy issue that could affect patients across the United States. In a joint letter addressed to Health and Human Services Secretary Robert F. Kennedy Jr., the lawmakers warned that emerging prediction markets allowing individuals to place bets on the outcomes of clinical trials and drug approvals undermine the scientific process.
Letter cites risks to research and patients
According to the letter, allowing bets on trial results creates “perverse incentives” for researchers, could lead participants to drop out of studies, and may tempt insiders to manipulate data for personal gain. The senators argue that such practices jeopardize the integrity of drug development and could result in dangerous medical outcomes for Americans.
Concerns about agency leadership
Alsobrooks, a vocal critic of Secretary Kennedy’s public‑health positions, referenced prior Senate hearings in which she accused the HHS head of fostering policies that she says have contributed to medical mistrust. She noted a recent resolution of no‑confidence she filed in May 2025, which initially garnered only four co‑signers but has since drawn broader attention.
Both senators also called for an investigation into alleged financial ties between Secretary Kennedy and anti‑vaccine groups, as well as potential improper gifts from major donors. They described recent agency actions as “costly, chaotic, and corrupt,” urging swift corrective measures.
Broader political context
Maryland Sen. Chris Van Hollen, who announced his candidacy for Senate Majority Leader, echoed the concerns, warning that unchecked betting on clinical trials could endanger public health under the current HHS leadership.
The senators’ appeal arrives amid growing national debate over how emerging financial technologies intersect with scientific research. While prediction markets have been praised in some circles for aggregating information, the lawmakers stress that the stakes in medical research are too high to allow profit‑driven speculation.
What could happen next?
If HHS acts on the letter, it could issue new regulations prohibiting prediction markets on clinical trials, enforce stricter data‑security protocols, and increase oversight of research funding. The administration has not yet responded publicly, but the senators indicated they expect a prompt reply given the potential risks to patient safety.
Stakeholders in the biotech and pharmaceutical sectors are watching closely, as any regulatory shift could affect how trial data is shared and how investors evaluate emerging therapies. Patient‑advocacy groups, meanwhile, have welcomed the call for greater protection of trial participants.
Local relevance
While the issue is national in scope, the letter underscores the role of Maryland and Oregon representatives in shaping federal health policy that ultimately impacts local hospitals, research institutions, and patients in their states. Residents of Baltimore, Annapolis, Portland, and surrounding communities can expect that any new HHS rules will influence how clinical studies are conducted locally.
Original reporting: The Washington Informer — read the source article.
